Our top pick for
ProSight Global Inc is an insurance-specialty business based in the US. ProSight Global shares (PROS) are listed on the NYSE and all prices are listed in US Dollars. ProSight Global employs 351 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$12.80|
|52-week range||$2.98 - $12.93|
|50-day moving average||$12.79|
|200-day moving average||$12.70|
|Wall St. target price||$12.85|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$1.14|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2022-01-17)||N/A|
|1 month (2021-12-24)||N/A|
|3 months (2021-10-24)||N/A|
|6 months (2021-07-28)||0.23%|
|1 year (2021-01-28)||2.56%|
|2 years (2020-01-28)||-16.34%|
|3 years (2019-01-24)||N/A|
|5 years (2017-01-24)||N/A|
Valuing ProSight Global stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ProSight Global's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
ProSight Global's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 11x. In other words, ProSight Global shares trade at around 11x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
ProSight Global's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $105.1 million.
The EBITDA is a measure of a ProSight Global's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$824.1 million|
|Operating margin TTM||12.56%|
|Gross profit TTM||$171 million|
|Return on assets TTM||2.23%|
|Return on equity TTM||10.71%|
|Market capitalisation||$562.6 million|
TTM: trailing 12 months
We're not expecting ProSight Global to pay a dividend over the next 12 months.
Over the last 12 months, ProSight Global's shares have ranged in value from as little as $2.98 up to $12.93. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while ProSight Global's is 0.4705. This would suggest that ProSight Global's shares are less volatile than average (for this exchange).
ProSight Global, Inc. , together with its subsidiaries, operates as an entrepreneurial specialty insurance company in the United States. It underwrites insurance coverages in the lines of commercial auto, general liability, workers' compensation, commercial multiple perils, and others. The company serves customers in construction, consumer service, marine and energy, media and entertainment, professional service, real estate, sports, and transportation industries. ProSight Global, Inc. was founded in 2009 and is headquartered in Morristown, New Jersey. .
Lido’s liquid staking allows investors holding LUNA and less than 32 ETH to reap the rewards of DeFi staking.
Downturns often let you buy fundamentally strong stocks at bargain prices, but mind the fundamentals and consider these 3 rules.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
Everything we know about the Specialty Building Products IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.